These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12464662)

  • 1. Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors.
    Al-Awqati Q
    J Clin Invest; 2002 Dec; 110(11):1599-601. PubMed ID: 12464662
    [No Abstract]   [Full Text] [Related]  

  • 2. New drug targets for cholera therapy.
    Thiagarajah JR; Verkman AS
    Trends Pharmacol Sci; 2005 Apr; 26(4):172-5. PubMed ID: 15808339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera.
    Sonawane ND; Hu J; Muanprasat C; Verkman AS
    FASEB J; 2006 Jan; 20(1):130-2. PubMed ID: 16317066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing novel antisecretory drugs to treat infectious diarrhea.
    de Hostos EL; Choy RK; Nguyen T
    Future Med Chem; 2011 Aug; 3(10):1317-25. PubMed ID: 21859305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera.
    Sonawane ND; Zhao D; Zegarra-Moran O; Galietta LJ; Verkman AS
    Gastroenterology; 2007 Apr; 132(4):1234-44. PubMed ID: 17408659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators.
    Noy E; Senderowitz H
    ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046
    [No Abstract]   [Full Text] [Related]  

  • 7. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.
    Cil O; Phuan PW; Gillespie AM; Lee S; Tradtrantip L; Yin J; Tse M; Zachos NC; Lin R; Donowitz M; Verkman AS
    FASEB J; 2017 Feb; 31(2):751-760. PubMed ID: 27871064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.
    de Jonge HR; Ardelean MC; Bijvelds MJC; Vergani P
    FEBS Lett; 2020 Dec; 594(23):4085-4108. PubMed ID: 33113586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological therapy for cystic fibrosis: from bench to bedside.
    Becq F; Mall MA; Sheppard DN; Conese M; Zegarra-Moran O
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S129-45. PubMed ID: 21658632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mGluR1 interacts with cystic fibrosis transmembrane conductance regulator and modulates the secretion of IL-10 in cystic fibrosis peripheral lymphocytes.
    Shanshiashvili LV; Dabrundashvili N; Natsvlishvili N; Kvaratskhelia E; Zhuravliova E; Barbakadze T; Koriauli S; Maisuradze E; Topuria T; Mikeladze DG
    Mol Immunol; 2012 Jul; 51(3-4):310-5. PubMed ID: 22520513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of alpha-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels.
    Routaboul C; Norez C; Melin P; Molina MC; Boucherle B; Bossard F; Noel S; Robert R; Gauthier C; Becq F; Décout JL
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1023-35. PubMed ID: 17578899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.
    Moss RB
    J Pediatr; 2013 Apr; 162(4):676-80. PubMed ID: 23290508
    [No Abstract]   [Full Text] [Related]  

  • 14. Cystic fibrosis transmembrane regulator inhibitors CFTR(inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition.
    Kelly M; Trudel S; Brouillard F; Bouillaud F; Colas J; Nguyen-Khoa T; Ollero M; Edelman A; Fritsch J
    J Pharmacol Exp Ther; 2010 Apr; 333(1):60-9. PubMed ID: 20051483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
    Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
    Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis.
    Kinnman N; Lindblad A; Housset C; Buentke E; Scheynius A; Strandvik B; Hultcrantz R
    Hepatology; 2000 Aug; 32(2):334-40. PubMed ID: 10915740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
    Bodewes FA; Wouthuyzen-Bakker M; Bijvelds MJ; Havinga R; de Jonge HR; Verkade HJ
    Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G1035-42. PubMed ID: 22301109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.